Xenetic Biosciences, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $3.0M | $2.5M | $2.5M | $1.7M | $1.2M |
| Operating income | -$2.8M | -$4.2M | -$4.5M | -$6.7M | -$5.7M |
| Operating expenses | $5.8M | $6.7M | $7.1M | $8.4M | $6.9M |
| Cash from operations | -$2.3M | -$2.8M | -$4.1M | -$4.6M | -$4.7M |
| Impairments | — | $700,000 | $0 | $0 | $0 |
| Total assets | $8.4M | $6.9M | $10.6M | $14.7M | $19.8M |
| Total liabilities | $968,025 | $894,263 | $809,585 | $1.1M | $1.4M |
Shares outstanding 2.3M · Free float 71.1%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.